Fine tuning subsets of CD4+ T cells by low‐dosage of IL‐2 and a new therapeutic strategy for autoimmune diseases

No abstract is available for this paper.

• Publication year

  2018

• Venue

  International Immunopharmacology

• Publication date

  2018-02-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.intimp.2018.01.042PMID 29414661
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low dose IL‐2 increase regulatory T cells and elevate platelets in a patient with immune thrombocytopenia

  2018cited by this paper
• CD8+ T cells of chronic HCV-infected patients express multiple negative immune checkpoints following stimulation with HCV peptides.

  2017cited by this paper
• Low‐dose interleukin‐2 promotes STAT‐5 phosphorylation, Treg survival and CTLA‐4‐dependent function in autoimmune liver diseases

  2017cited by this paper
• T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation

  2017cited by this paper
• Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study

  2016cited by this paper
• Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells.

  2016cited by this paper
• T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

  2016cited by this paper
• Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial

  2016cited by this paper
• Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2

  2016cited by this paper
• Empowering Regulatory T Cells in Autoimmunity.

  2016cited by this paper
• An essential role for IL-2 receptor in regulatory T cell function

  2016cited by this paper
• In vivo induction of regulatory T cells for immune tolerance in hemophilia.

  2016cited by this paper
• Comparative Analysis of Protocols to Induce Human CD4+Foxp3+ Regulatory T Cells by Combinations of IL-2, TGF-beta, Retinoic Acid, Rapamycin and Butyrate

  2016cited by this paper
• Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus

  2016cited by this paper
• Time-Dependent Regulation of IL-2R α-Chain (CD25) Expression by TCR Signal Strength and IL-2-Induced STAT5 Signaling in Activated Human Blood T Lymphocytes

  2016cited by this paper
• The role of cytokines in the pathogenesis of cutaneous lupus erythematosus.

  2015cited by this paper
• Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE

  2015cited by this paper
• Regulatory T cells require the phosphatase PTEN to restrain type 1 and follicular helper T-cell responses

  2015cited by this paper
• Regulatorische T-Zellen und rheumatische Erkrankungen

  2015cited by this paper
• Circulating Follicular Helper–Like T Cells in Systemic Lupus Erythematosus: Association With Disease Activity

  2015cited by this paper
• A mechanism for expansion of regulatory T cell repertoire and its role in self tolerance

  2015cited by this paper
• Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.

  2015cited by this paper
• Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

  2015cited by this paper
• Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes

  2015cited by this paper
• Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.

  2015cited by this paper
• IL-2: The First Effective Immunotherapy for Human Cancer

  2014cited by this paper
• Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata.

  2014cited by this paper
• The phosphatase PTEN-mediated control of PI-3 kinase in Tregs cells maintains homeostasis and lineage stability

  2014cited by this paper
• PD‐1 regulates extrathymic regulatory T‐cell differentiation

  2014cited by this paper
• Clinical associations of serum interleukin-17 in systemic lupus erythematosus

  2013cited by this paper
• Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease

  2013cited by this paper
• Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.

  2013cited by this paper
• Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

  2012cited by this paper
• The role of interleukin-2 during homeostasis and activation of the immune system

  2012cited by this paper
• Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials

  2012cited by this paper
• Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation.

  2012cited by this paper
• Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

  2011cited by this paper
• Interleukin-2 and regulatory T cells in graft-versus-host disease.

  2011cited by this paper
• Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells

  2011cited by this paper
• Human FoxP3+ regulatory T cells in systemic autoimmune diseases.

  2011cited by this paper
• Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.

  2011cited by this paper
• Regulatory T Cells: Customizing for the Clinic

  2011cited by this paper
• Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.

  2011cited by this paper
• The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism.

  2010cited by this paper
• IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells

  2010cited by this paper
• Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo.

  2010cited by this paper
• Interleukin-2 receptor signaling: at the interface between tolerance and immunity.

  2010cited by this paper
• Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases

  2010cited by this paper
• Regulatory T cells exert checks and balances on self tolerance and autoimmunity

  2010cited by this paper
• Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus

  2009cited by this paper
• Low-dose IL-2 therapy reduces HCV RNA and HBV DNA: case report.

  2009cited by this paper
• Quality of life after allogeneic hematopoietic cell transplantation.

  2009cited by this paper
• The biology of interleukin-2.

  2008cited by this paper
• The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2).

  2008cited by this paper
• Immunological mechanisms and clinical implications of regulatory T cell deficiency in a systemic autoimmune disorder: Roles of IL‐2 versus IL‐15

  2008cited by this paper
• Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells.

  2008cited by this paper
• Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.

  2008cited by this paper
• Effect of Low-Dose IL-2 Immunotherapy on Frequency and Phenotype of Regulatory T Cells and NK Cells in HIV/HCV-Coinfected Patients

  2008cited by this paper
• IL-2, -7, and -15, but Not Thymic Stromal Lymphopoeitin, Redundantly Govern CD4+Foxp3+ Regulatory T Cell Development1

  2008cited by this paper
• Nonredundant roles for Stat5a/b in directly regulating Foxp3.

  2007cited by this paper
• Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.

  2007cited by this paper
• Function of the IL-2R for Thymic and Peripheral CD4+CD25+ Foxp3+ T Regulatory Cells1

  2007cited by this paper
• Interleukin-2 receptor signaling in regulatory T cell development and homeostasis.

  2007cited by this paper
• Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.

  2007cited by this paper
• Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans

  2007cited by this paper
• IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.

  2006cited by this paper
• Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.

  2005cited by this paper
• A function for interleukin 2 in Foxp3-expressing regulatory T cells

  2005cited by this paper
• CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis.

  2004cited by this paper
• Distinct IL-2 Receptor Signaling Pattern in CD4+CD25+ Regulatory T Cells1

  2004cited by this paper
• IL-2, Regulatory T Cells, and Tolerance

  2004cited by this paper
• CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

  2004cited by this paper
• Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

  2003cited by this paper
• Distinct Effects of STAT5 Activation on CD4+ and CD8+ T Cell Homeostasis: Development of CD4+CD25+ Regulatory T Cells versus CD8+ Memory T Cells 1

  2003cited by this paper
• CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation

  2003cited by this paper
• CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2.

  2002cited by this paper
• The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

  2001cited by this paper
• Normal Lymphoid Homeostasis and Lack of Lethal Autoimmunity in Mice Containing Mature T Cells with Severely Impaired IL-2 Receptors1

  2000cited by this paper
• Blocking the Common γ-Chain of Cytokine Receptors Induces T Cell Apoptosis and Long-Term Islet Allograft Survival1

  2000cited by this paper
• Biology of the interleukin-2 receptor.

  1998cited by this paper
• Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta.

  1995cited by this paper
• Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment.

  1995cited by this paper
• Generalized autoimmune disease in interleukin‐2‐deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells

  1995cited by this paper
• Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene.

  1993cited by this paper
• In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

  1985cited by this paper
• Gene for T-cell growth factor: location on human chromosome 4q and feline chromosome B1.

  1984cited by this paper
• Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE).

  1983cited by this paper
• Structure and expression of a cloned cDNA for human interleukin-2

  1983cited by this paper
• Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors.

  1979cited by this paper
• Revised nomenclature for antigen-nonspecific T-cell proliferation and helper factors.

  1979cited by this paper
• Selective in vitro growth of T lymphocytes from normal human bone marrows.

  1976cited by this paper

• A Granzyme B-Cleavable T Cell-Targeted Bispecific Cell Vesicle Connector for Reversing New-Onset Type 1 Diabetes.

  2025cites this paper
• Lipid Metabolism in Pregnancy Women with Hypothyroidism and Potential Influence on Pregnancy Outcome

  2024cites this paper
• The effects of low-dose IL-2 on Th17/Treg cell imbalance in primary biliary cholangitis mouse models

  2024cites this paper
• Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity

  2023cites this paper
• The effects of Lactobacillus delbrueckii and Lactobacillus rhamnosus on cytokines and their related molecules: An ex vivo study on patients with systemic lupus erythematosus

  2023cites this paper
• Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

  2023cites this paper
• Allogenic Umbilical Cord-Derived Mesenchymal Stromal Cells Sustain Long-Term Therapeutic Efficacy Compared With Low-Dose Interleukin-2 in Systemic Lupus Erythematosus

  2023cites this paper
• New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases.

  2022cites this paper
• The emerging role of regulatory cell-based therapy in autoimmune disease

  2022cites this paper
• Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus

  2022cites this paper
• Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells.

  2021cites this paper
• Mass cytometry reveals cellular fingerprint associated with IgE+ peanut tolerance and allergy in early life

  2020cites this paper
• Regulatory T cell heterogeneity and therapy in autoimmune diseases.

  2020cites this paper
• Engineering IL-2 to Give New Life to T Cell Immunotherapy.

  2020cites this paper
• Airways therapy of obstructive sleep apnea dramatically improves aberrant levels of soluble cytokines involved in autoimmune disease.

  2020cites this paper
• Autoimmune hematologic complications of umbilical cord blood transplantation.

  2020cites this paper
• Tumor-induced Metabolism and T Cells Located in Tumor Environment.

  2020cites this paper
• T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

  2020cites this paper
• Mechanisms of action of low-dose IL-2 restoration therapies in SLE.

  2019cites this paper
• SAT0012 DETECTION OF CIRCULATING PR3-SPECIFIC B CELLS IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS

  2019cites this paper
• Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature

  2018cites this paper
• Apigenin reverses lung injury and immunotoxicity in paraquat‐treated mice

  2018cites this paper